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Abstract
Introduction: Leiomyosarcomas are neoplasms of smooth muscles that most commonly arise from the uterus,
gastrointestinal tract, or soft tissue. Primary pleural leiomyosarcoma is extremely rare. To the best of our
knowledge, only nine cases have been published to date. Because of the rarity of pleural leiomyosarcoma and its
similarity (clinical and histological) to other pleural neoplasms, particularly sarcomatous mesothelioma, diagnosis is
often difficult.
Case presentation: A 58-year-old North African man was admitted with complaints of dyspnea and chest pain to
our hospital. Chest computed tomography revealed right pleural effusion and pleural thickening. A transthoracic
needle biopsy yielded a diagnosis of leiomyosarcoma, and tumor cells were strongly and uniformly positive for
vimentin, a smooth muscle actin at immunohistochemical analysis. A general examination did not show any
metastatic lesions in other areas. One month after diagnosis, the tumor grew rapidly, with pulmonary invasion, and
therefore he was treated only by palliative care. He died from respiratory failure one month later. Because no
organ of origin of the leiomyosarcoma, other than the pleura, was detected, this case was diagnosed as a primary
pleural leiomyosarcoma.
Conclusions: Although leiomyosarcoma originating from the pleura is rare, this entity is increasingly described. The
purpose of presenting this case report is to raise awareness among clinicians to consider this clinical entity as a
differential diagnosis when a pleural mass is identified.
Introduction
Leiomyosarcomas are cancers of smooth muscle cells
that can arise from any location but occur most often in
the uterus, retroperitoneum, or intra-abdominal region.
Primary pleural leiomyosarcomas are extremely rare
[1,2]. There are few reports of individual cases [1-5], but
no large series from a single institution has been pub-
lished. On radiological examination, primary pleural
leiomyosarcoma presents as a mass or a pleural effusion.
Metastasis is uncommon and typically occurs late in the
disease process, underscoring the importance of early
detection. When primary pleural leiomyosarcoma is
seen in the pleura, it is important to establish whether
the tumor originated in the lung or is secondary to
metastases from a separate location, the latter of which
is much more common.
To definitively establish the pleura as the primary site
for leiomyosarcoma, all other possible sites of origin
within the body must be excluded. Therefore, diagnosis
is difficult and management is complete resection of the
tumor if feasible [4,6,7]. In this report, a rare primary
pleural leiomyosarcoma exhibiting rapid growth and
fatal outcome is described. The diagnostic approach to
our patient is presented and the pertinent literature is
reviewed.
Case presentation
A 58-year-old North African man presented with com-
plaints of dyspnea and right-sided chest pain for the
previous two months. He had a 25-year history of
tobacco use, smoking one pack of cigarettes per day for
25 years, but had no additional risk factors. Three liters
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any medium, provided the original work is properly cited.of his chest in another hospital and then was referred to
our hospital for further evaluation and management. A
biochemical analysis of the pleural fluid revealed that
the nucleated cell count was 7800/mm
3 (23% neutro-
phils and 71% lymphocytes), total protein concentration
was 32 g/dL (a pleural fluid-to-serum ratio of 0.52), lac-
tate dehydrogenase level was 460 IU/L, and glucose
level was 110 mg/dL. The pH of the pleural fluid was
7.30. These findings were consistent with exudative
pleural effusion. The results of pleural fluid cytology
were negative for malignant cells. The pleural fluid was
cultured for bacteria (aerobic and anaerobic), fungi, and
mycobacteria, and the results were negative. During a
clinical examination, the breath sounds were decreased
on the right side. A chest radiograph showed the pre-
sence of an opaque right hemithorax, and the mediasti-
num was pushed toward the right (Figure 1). Computed
tomography (CT) of the chest revealed a right-sided cav-
ity with thick and irregular walls extending throughout
the pleural space in the right lower lobe, pleural effu-
sion, and a partially collapsed right lung (Figure 2). An
interventional radiologist performed a transthoracic nee-
dle pleural biopsy, which revealed a mesenchymal lesion
consistent with a smooth muscle cell-type lesion. On
microscopic examination, the tumor consisted of neo-
plastic spindle cell proliferation arranged in interlacing
bundles with hyperchromatic nuclei and frequent
mitoses (greater than 10 mitoses per 10 high-power
fields) (Figure 3). No areas of hemorrhage or necrosis
were seen. Immunohistochemistry (IHC) staining was
performed. The panel of monoclonal antibodies con-
sisted of cytokeratin 5/6, 7, and 20, vimentin, smooth
muscle actin, calretinin, CD-117, TTF1, EMA, CD-34,
and S-100 protein. The tumor cells were positive for
vimentin and smooth muscle actin strongly and uni-
formly (Figures 4 and 5). These cells were immunonega-
tive for all other markers tested, ruling out carcinoma
(cytokeratin), sarcomatous mesothelioma (calretinin),
solitary fibrous tumor (CD-34), and neurogenic sarcoma
(S-100 protein) (Figures 6 and 7). After the pathological
diagnosis, a CT scan of the whole body was performed
but did not reveal any tumors. The authors diagnosed
the lesion as primary pleural leiomyosarcoma. However,
the tumor grew rapidly, with pleural effusion. Our
patient was treated only by palliative care. He died one
month later due to acute respiratory failure.
Discussion
Leiomyosarcomas are neoplasms of smooth muscles that
most commonly arise from the uterus, gastrointestinal
tract, or soft tissue. Pleural leiomyosarcomas originating
in the serosal membranes are even more unusual and
Figure 1 Chest radiograph (postero-anterior view) shows the presence of a right-sided opaque hemithorax.
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Page 2 of 7Figure 2 Selected sections of a conventional computed tomography scan of the chest. The scan shows a right-sided cavity with thick and
irregular walls in the right lower lobe, pleural effusion, and a partially collapsed right lung.
Figure 3 Biopsy shows neoplastic spindle cell proliferation arranged in interlacing bundles and fascicles. Stain: hematoxylin and eosin;
magnification: 40×.
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tumors are classified as sarcomatous types of mesothe-
lioma when they are diffuse and as variants of solitary
fibrous tumors when they are localized [3,5].
To the best of our knowledge, no large series has
documented the exact number of pleural leiomyosar-
coma cases worldwide. Data are available in isolated
case reports and small case series. To the best of our
Figure 4 Tumor cells show strong positivity for anti-acute myeloid leukemia. Stain: immunohistochemical; magnification: 20×.
Figure 5 Immunohistochemical staining reveals diffuse and strongly positive reactions with anti-vimentin antibodies. Magnification: 20×.
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[4-6]. Thanks to increasing awareness of this entity and
increasing application of adjunctive diagnostic tools,
more cases will be diagnosed in the future.
Clinically, pleural leiomyosarcoma resembles other
primary tumors of the pleura in symptomatology (dys-
pnea, chest pain, or cough), physical signs, and radiology
[5,6]. On radiological examination, a mass lesion or
pleural effusion or both are common, as in our case. In
some cases, the tumor encases the lung, similarly to
mesothelioma [5,7].
Extrathoracic primary tumors should be excluded by
physical examination and CT. Most pleural leiomyosar-
comas are metastatic from other sites, including the gas-
trointestinal tract, uterus, retroperitoneum, and lung
[1-4]. So exclusion of metastatic leiomyosarcoma in the
pleura is an essential step in diagnosing the primary
lesion. In all reported cases, a localized unilateral pleural
lesion with no abnormality detected on careful examina-
tion of the soft tissue, gastrointestinal tract, and
genitourinary tract suggested primary disease of the
pleura [2-7]. The lesion in this case report is primary
pleural leiomyosarcoma because imaging modalities,
including CT, revealed no tumors other than the pleural
tumor.
On reviewing the literature on pleural leiomyosar-
coma, we found that most of the cases were diagnosed
by surgical biopsy at either thoracoscopy or thoracot-
omy [1,3]. Occasionally, the diagnosis has been made by
CT-guided transthoracic biopsy, according to isolated
reports [4,7]. Histological examination supplemented
with IHC staining studies is the most reliable and con-
clusive method of diagnosing leiomyosarcoma and dif-
ferentiating it from other more frequent primary pleural
malignancies, such as malignant mesothelioma (sarco-
matous), malignant fibrous histiocytoma, solitary fibrous
tumor of pleura, synovial sarcoma, and neurogenic
tumors.
Microscopically, leiomyosarcomas are characterized by
malignant spindle cells with cigar-shaped nuclei and
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Figures 6 Immunohistochemistry shows that the tumor cells are negative for cytokeratin 7 (A), cytokeratin 20 (B), calretinin (C), and
PS-100 (D). Magnifications: 200×.
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observed [1,4,5]. However, because of the rarity of
pleural leiomyosarcoma and its similarity (clinical and
histological) to other pleural neoplasms, particularly sar-
comatous mesothelioma, pathological diagnosis is often
difficult.
Therefore, the use of an antibody panel is recom-
mended in order to confirm the diagnosis of pleural
leiomyosarcoma and to rule out a commonly considered
differential diagnosis. Immunohistochemically, leiomyo-
sarcomas are nearly uniformly positive for smooth mus-
cle actin, desmin, and vimentin and negative for
calretinin, carcinoembryonic antigen, cytokeratin, leuko-
cyte common antigen, neuroendocrine filament, CD-
117, and S-100 protein [4,5]. In our case report, histolo-
gical and immunohistochemical characteristics of the
tumors studied were basically similar and conformed to
those described by other authors.
Histopathology and IHC staining have been supple-
mented by cytogenetic analyses, which can confirm the
diagnosis of leiomyosarcoma [5]. Cytogenetic studies of
t h es m o o t hm u s c l et u m o ro ft h ep l e u r ah a v er e v e a l e d
contained chromosomal losses at 10q and 13q, which
are the most common losses described in soft tissue
leiomyosarcomas [8].
The optimal treatment for pleural leiomyosarcoma has
not been defined. Surgery is the mainstay of therapy for
pleural sarcoma in limited disease, and even in some
cases having local spread, resection was feasible [1,6,7,9].
Multi-modal therapy, including surgery and radiation,
has also been used. The need for adjuvant radiation or
chemotherapy may be assessed on a case-by-case basis
depending on the histological grade of the tumor and
the clinical stage at the time of diagnosis [9]. In the lit-
erature, the most common treatment is surgical resec-
tion alone or surgery with adjuvant radiation therapy
[4-7].
As with leiomyosarcomas of other soft tissue sites, his-
tological grade and clinical stage of the disease are the
best prognostic factors. Patients with unresectable sar-
coma or metastatic disease are treated with chemother-
apy [10]. Leiomyosarcomas are chemosensitive to
doxorubicin, ifosfamide, and trabectedin, and the overall
response rate is approximately 20% [11]. The median
survival for patients with extensive disease is about 12
months [10,11]. In our case report, pleural
;Ϳ ;Ϳ
Figure 7 Immunohistochemistry shows that the tumor cells are negative for CD-117 (A) and CD-34 (B). Magnifications: 200×.
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sis because of the frequency of this infection in Mor-
occo. The diagnosis of pleural leiomyosarcoma was
made later, after deterioration of the general condition
of our patient and aggressive progression of the tumor,
which was unresectable.
Conclusions
The addition of our case to the literature offers new
clinicopathological data useful for better defining the
diagnosis and biological behavior of pleural leiomyosar-
coma. The purpose of presenting this case report is not
only to report an uncommon pleural tumor but also to
raise awareness among clinicians adding this clinical
entity as a differential diagnosis when a pleural mass is
identified.
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